The Bacillus Calmette-Guérin vaccine, commonly called BCG, began as an attempt to protect against tuberculosis in the early twentieth century. Developed from a weakened strain of Mycobacterium bovis, it remains one of the most widely administered vaccines in the world, given to newborns in many high-burden countries. Its record against the disease that prompted its creation is uneven, and recent trials have clarified both its strengths and its boundaries.
Randomized controlled trials conducted decades ago established that BCG reduces the risk of severe, disseminated forms of tuberculosis in young children. Protection against pulmonary disease in adults has proven harder to demonstrate consistently. Geographic variation appears in the data, with stronger signals in some temperate settings and weaker ones nearer the equator. Observational studies suggested possible non-specific benefits against other infections, yet those designs cannot rule out differences in healthcare access or reporting that might explain the patterns.
The BCG REVAX trial, reported in the New England Journal of Medicine in May 2025, tested revaccination in HIV-negative adolescents in South Africa who tested negative on interferon-gamma release assays. The study used a randomized, placebo-controlled design and focused on a pre-specified primary endpoint: sustained QuantiFERON conversion, a marker of persistent Mycobacterium tuberculosis infection. After a median follow-up of thirty months, conversion rates were nearly identical between groups. The hazard ratio stood at 1.04, yielding a point estimate of vaccine efficacy near negative three percent. Injection-site reactions occurred more often with BCG, as expected from a live vaccine.
That result does not erase BCG's established role in infant schedules. It does illustrate how endpoint selection and population matter. Earlier, smaller studies had hinted at protection against sustained infection; the larger, later trial with harmonized protocols did not confirm the signal. Methodologists note that such discrepancies often trace to differences in follow-up duration, assay cut-offs, or background exposure rates rather than outright contradiction.
BCG found an entirely different application in oncology. Intravesical instillation after transurethral resection became standard care for many patients with non-muscle-invasive bladder cancer. Multiple randomized trials and meta-analyses have shown reductions in recurrence compared with resection alone or with certain chemotherapies. Maintenance schedules further lower the odds of progression to muscle-invasive disease in higher-risk cases. Response rates for carcinoma in situ reach roughly seventy percent in appropriately selected patients, though roughly forty percent eventually recur.
A study published in Cancer Cell on May 29, 2025, from researchers at Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine examined how the therapy works beyond the bladder. The team mapped changes in bone-marrow stem and progenitor cells that give rise to myeloid immune cells. BCG administration altered the programming of these cells, amplifying their capacity to support anti-tumor responses systemically. Mouse experiments showed improved tumor control when BCG was paired with checkpoint inhibitors. The findings suggest trained innate immunity contributes to the observed clinical effects, an observation that aligns with earlier hints from infant vaccination data but now rests on direct cellular evidence in the cancer setting.
Researchers continue to explore whether modified or alternative delivery routes could extend BCG's utility against tuberculosis. Work in Australia has examined inhaled formulations designed to engage lung-resident immune cells more directly. Early preclinical results indicate stronger local T-cell responses than standard intradermal administration, though human safety and efficacy data remain limited. Genetically altered strains that retain immunogenicity while reducing virulence are also under investigation.
Follow-up from the BATTLE randomized trial, published in 2025, reported that BCG given after recovery from acute COVID-19 was associated with roughly a thirty percent lower incidence of long COVID symptoms at six and twelve months. The double-blind, placebo-controlled design strengthens the observation, yet the mechanism and durability require further confirmation in independent cohorts. Similar lines of inquiry have examined BCG in healthcare-worker populations during earlier pandemic waves, with mixed signals depending on timing and endpoint.
Across these domains, the arithmetic of evidence favors well-powered randomized designs with clinically relevant endpoints over smaller or observational work. BCG remains a tool with documented value in specific contexts: infant tuberculosis prevention and adjuvant therapy for certain bladder cancers. Its limitations in adult pulmonary tuberculosis and the absence of benefit from revaccination in one recent adolescent trial underscore that live attenuated mycobacterial vaccines do not confer blanket protection. Ongoing trials of newer candidates will show whether those gaps can be closed without sacrificing the safety profile that has allowed BCG to persist for a century.